Leucid Bio

Leucid Bio is a UK-based biotech translating 20+ years of academic research into a novel CAR-T platform designed for enhanced potency and durability. Founded on the pioneering work of Dr. John Maher at King's College London, the company's 'Lateral CAR' technology reconfigures signaling domains to improve T-cell function and persistence. With its lead asset, LEU011, now in a Phase 1 trial for solid tumors and backed by experienced leadership and notable investors, Leucid aims to address significant unmet needs in oncology, particularly in hard-to-treat cancers where current CAR-T therapies have limited efficacy.

Proprietary Lateral CAR platform that re-engineers the CAR structure to position signaling domains laterally (next to the plasma membrane) rather than linearly, aiming to mimic natural immune receptor signaling for enhanced T-cell potency, persistence, and reduced toxicity.

Leucid competes in the crowded and rapidly evolving CAR-T therapy landscape, dominated by large players like Novartis, Gilead/Kite, and Bristol Myers Squibb in blood cancers. Its key differentiation is its Lateral CAR platform architecture, aiming for superior T-cell function. In solid tumors, it faces competition from numerous biotechs exploring novel targets, armoring strategies, and allogeneic approaches. Its success hinges on demonstrating clear clinical advantages from its unique engineering.